Fuzuloparib

Spinal Cord Injury

Centre National de Rééducation Fonctionnelle et de RéadaptationN/AActive

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 81/ 100

Competitive context

10 Active assets in the Spinal Cord Injury cohort.

Asset / Sponsor	Phase	Rating
Oxcarbamezapine Ju Seok Ryu	Phase 4	BB
Xeomin® Catholic University of Korea Saint Paul's Hospital	Phase 4	B
Marijuana Khon Kaen University	Phase 2/3	B
Tizanidine Elan Pharmaceuticals	Phase 3	B
Dextromethorphan Brigham and Women's Hospital	Phase 2	B

View all 19 →

Same molecule, other indications

Fuzuloparib is also rated in:

Obese Patients With Prostate Cancer DiseaseDormant

B

Indicative ·

60 / 100

Chronic Postsurgical PainDormant

B

Indicative ·

60 / 100

triple-negative breast carcinomaDormant

B

Indicative ·

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.